TheraRadar
Data updated: May 26, 2026

NATACYN (natamycin)

Trial Activity: Stable 1 active trials
Ophthalmology Approved 1978-10-30

NATACYN is indicated for the treatment of Fungal Blepharitis; Conjunctivitis; Keratitis; Fusarium Solani Keratitis.

Source: FDA Label • HARROW EYE
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

Development Insights

University of California, San Francisco conducting 3 trials (75%)
4 indications explored (Focused)
→ fungal keratitis (3 trials)
→ corneal ulcer (2 trials)
→ acanthamoeba keratitis (1 trials)
1
Indication
--
Phase 3 Trials
1
Priority Reviews
47
Years on Market

Details

Status
Prescription
First Approved
1978-10-30
Routes
OPHTHALMIC
Dosage Forms
SUSPENSION

Companies

HARROW EYE
Active Ingredient: NATAMYCIN

NATACYN Approval History

1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
10 FDA actions from 1978 to 2025
Nov 2025 SUPPL
Label · Labeling
FDA Letter Label
Jul 2008 SUPPL
Label · Labeling
FDA Letter Label
Dec 2002 SUPPL Priority
Mfg · Manufacturing (CMC)

What NATACYN Treats

4 indications

NATACYN is approved for 4 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Fungal Blepharitis
  • Conjunctivitis
  • Keratitis
  • Fusarium Solani Keratitis
Source: FDA Label

NATACYN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

3

Same indication, different mechanism — what else might this patient receive?

CIPRODEX
Novartis
2003 2 indic.
OCUFLOX
AbbVie
1993 2 indic.
Unlock 1 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NATACYN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CIPRODEX
CIPROFLOXACIN
1 shared
Novartis
Shared indications:
Conjunctivitis
OCUFLOX
OFLOXACIN
1 shared
AbbVie
Shared indications:
Conjunctivitis
SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM
1 shared
FOUGERA PHARMS
Shared indications:
Conjunctivitis
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05110001 REAGIR results posted 18-26045-R UG1EY028518 Ph 3 completed Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
NCT02731638 MALIN results posted 15-17989 Ph 3 completed Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
NCT00996736 MUTT I results posted H9332-33965-02 U10EY018573-01A1 Ph 3 completed Mycotic Ulcer Treatment Trial I
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NATACYN FDA Label Details

Indications & Usage

FDA Label (PDF)

NATACYN is indicated for the treatment of Fungal Blepharitis; Conjunctivitis; Keratitis; Fusarium Solani Keratitis.

Track NATACYN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA050514 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment